Anixa expands cancer vaccine collaboration with Cleveland Clinic [Yahoo! Finance]
Anixa Biosciences, Inc. (ANIX)
Last anixa biosciences, inc. earnings: 3/9 05:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Cleveland Clinic is undertaking a Phase I clinical trial for triple-negative breast cancer, the most lethal form of the disease. A vaccine for ovarian cancer, currently in pre-clinical stages, is also being developed by Cleveland in partnership with the National Cancer Institute. The vaccines aim to immunise against "retired" proteins expressed in specific cancer forms. The goal is to destroy emerging cancer cells and prevent the formation of tumours. Developed at Cleveland, the vaccines have been licensed to Anixa Biosciences. Cleveland Clinic will receive royalties and other commercialisation revenues. The new joint development agreement research will be led by Cleveland Clinic's department of inflammation and immunity chair, Thaddeus Stappenbeck. Justin Johnson, a co-inventor of the breast and ovarian cancer vaccines, will also be involved in the research. Anixa chairman and CEO Dr Amit Kumar stated: “Cleveland Clinic is a valued partner to Anixa in the development o
Show less
Read more
Impact Snapshot
Event Time:
ANIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIX alerts
High impacting Anixa Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ANIX
News
- Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical TrialPR Newswire
- Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines [Yahoo! Finance]Yahoo! Finance
- Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer VaccinesPR Newswire
- Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja [Yahoo! Finance]Yahoo! Finance
ANIX
Earnings
- 9/6/23 - Beat
ANIX
Analyst Actions
- 3/21/24 - HC Wainwright
ANIX
Sec Filings
- 5/8/24 - Form 8-K
- 5/3/24 - Form SC
- 5/2/24 - Form 4
- ANIX's page on the SEC website